Dominari (NASDAQ:DOMH – Get Free Report) and Context Therapeutics (NASDAQ:CNTX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.
Insider & Institutional Ownership
42.5% of Dominari shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 33.0% of Dominari shares are owned by insiders. Comparatively, 2.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Dominari has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dominari | 0 | 0 | 0 | 0 | 0.00 |
| Context Therapeutics | 0 | 0 | 5 | 1 | 3.17 |
Context Therapeutics has a consensus price target of $5.50, indicating a potential upside of 733.08%. Given Context Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Dominari.
Profitability
This table compares Dominari and Context Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dominari | -167.73% | -91.67% | -77.80% |
| Context Therapeutics | N/A | -29.78% | -29.08% |
Valuation & Earnings
This table compares Dominari and Context Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dominari | $18.15 million | 4.48 | -$14.70 million | ($4.50) | -1.23 |
| Context Therapeutics | N/A | N/A | -$26.73 million | ($0.31) | -2.13 |
Dominari has higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.
Summary
Context Therapeutics beats Dominari on 9 of the 14 factors compared between the two stocks.
About Dominari
Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.
About Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Receive News & Ratings for Dominari Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dominari and related companies with MarketBeat.com's FREE daily email newsletter.
